Alain Beck

Dr Alain Beck is Senior Director, Biologics CMC and developability (Pierre Fabre), Associate Editor of mAbs (2009) and chairman of MabDesign SAB (2014). He is or was involved in 9 clinical stage biologics R&D programs including dalotuzumab (Merck), telisotuzumab/ telisotuzumab vedotin (AbbVie), W0101 ADC and K01401-020 Vista mAb (PF). He is author/ co-author of +230 publications (h-index: 50; +10 500 citations). He has contributed to more than 150 scientific meetings (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC) as chairman, invited speaker, panelist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, BsAbs, Fc-fusions, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013) and is the 6th World ADC Awards winner for long standing contribution to the field (2019). He is member of the MAB Working Party (EDQM/PhEur) and involved in meetings with ANSM, EU, EMA, FDA, NIST, USP and WHO.